Sara Olofsson1, Hanna Norrlid2, Eva Karlsson3, Ulla Wilking4, Gunnel Ragnarson Tennvall5. 1. IHE, The Swedish Institute for Health Economics, Box 2127, SE-220 20 Lund, Sweden; Department of Clinical Sciences, Lund University, Sweden. Electronic address: so@ihe.se. 2. IHE, The Swedish Institute for Health Economics, Box 2127, SE-220 20 Lund, Sweden. Electronic address: hn@ihe.se. 3. Department of Oncology, Skåne University Hospital, SE-221 85 Lund, Sweden. Electronic address: eva.u.karlsson@skane.se. 4. Karolinska Institutet, Department of Oncology-Pathology, Karolinska University Hospital Solna, Z1:00, SE-171 76 Stockholm, Sweden. Electronic address: ulla.wilking@ki.se. 5. IHE, The Swedish Institute for Health Economics, Box 2127, SE-220 20 Lund, Sweden. Electronic address: grt@ihe.se.
Abstract
INTRODUCTION: Trastuzumab is part of the standard treatment for HER2-positive breast cancer. The aim of this study was to estimate the societal value of trastuzumab administered through subcutaneous (SC) injection compared to intravenous (IV) infusion. METHODS: Female patients with HER2-positive breast cancer receiving SC or IV trastuzumab were consecutively enrolled from five Swedish oncology clinics from 2013 to 2015. Data on time and resource utilization was collected prospectively using patient and nurse questionnaires. Societal costs were calculated by multiplying the resource use by its corresponding unit price, including direct medical costs (pharmaceuticals, materials, nurse time, etc.), direct non-medical costs (transportation) and indirect costs (production loss, lost leisure time). Costs were reported separately for patients receiving trastuzumab for the first time and non-first time ("subsequent treatment"). RESULTS: In total, 101 IV and 94 SC patients were included in the study. The societal costs were lower with SC administration. For subsequent treatments the cost difference was €117 (IV €2099; SC €1983), partly explained by a higher time consumption both for nurses (14 min) and patients (23 min) with IV administration. Four IV and 16 SC patients received trastuzumab for the first time and were analysed separately, resulting in a difference in societal costs of €897 per treatment. A majority of patients preferred SC to IV administration. CONCLUSION: SC administration resulted in both less direct medical costs and indirect costs, and was consequently less costly than IV administration from a societal perspective in a Swedish setting.
INTRODUCTION:Trastuzumab is part of the standard treatment for HER2-positive breast cancer. The aim of this study was to estimate the societal value of trastuzumab administered through subcutaneous (SC) injection compared to intravenous (IV) infusion. METHODS: Female patients with HER2-positive breast cancer receiving SC or IV trastuzumab were consecutively enrolled from five Swedish oncology clinics from 2013 to 2015. Data on time and resource utilization was collected prospectively using patient and nurse questionnaires. Societal costs were calculated by multiplying the resource use by its corresponding unit price, including direct medical costs (pharmaceuticals, materials, nurse time, etc.), direct non-medical costs (transportation) and indirect costs (production loss, lost leisure time). Costs were reported separately for patients receiving trastuzumab for the first time and non-first time ("subsequent treatment"). RESULTS: In total, 101 IV and 94 SC patients were included in the study. The societal costs were lower with SC administration. For subsequent treatments the cost difference was €117 (IV €2099; SC €1983), partly explained by a higher time consumption both for nurses (14 min) and patients (23 min) with IV administration. Four IV and 16 SC patients received trastuzumab for the first time and were analysed separately, resulting in a difference in societal costs of €897 per treatment. A majority of patients preferred SC to IV administration. CONCLUSION: SC administration resulted in both less direct medical costs and indirect costs, and was consequently less costly than IV administration from a societal perspective in a Swedish setting.
Authors: Luis Rojas; Sabrina Muñiz; Lidia Medina; Jose Peña; Francisco Acevedo; Mauricio P Pinto; Cesar Sanchez Journal: PLoS One Date: 2020-02-05 Impact factor: 3.240
Authors: Margreet Franken; Tim Kanters; Jules Coenen; Paul de Jong; Agnes Jager; Carin Uyl-de Groot Journal: Breast Date: 2020-05-16 Impact factor: 4.380
Authors: Yohei Ozawa; Kristin C Hicks; Christine M Minnar; Karin M Knudson; Jeffrey Schlom; Sofia R Gameiro Journal: Oncoimmunology Date: 2021-05-03 Impact factor: 8.110
Authors: Bruce C Roberts; Christopher Rini; Rick Klug; Douglas B Sherman; Didier Morel; Ronald J Pettis Journal: Drug Deliv Date: 2022-12 Impact factor: 6.419